Disponibile dal lunedi al venerdi previo appuntamento da concordare via e-mail
2018- to date Assistant Professor of Biochemistry
2016-2018 Fondazione Veronesi Postdoctoral fellowship at University of Florence (UniFi)
2013-2015 Postdoc at UniFI funded by Fondazione Italiana Ricerca Cancro (FIRC)
2010-2013 Postdoc at ICR (Institute of Cancer Research, London, UK)
2007-2008 Visiting PhD student at ICR
2007-2009 PhD student at UniFi
2004-2006 Research intern at the Dipartimento di Patologia e Oncologia Sperimentali at UniFi
2017 Biochemistry Lecturer at UniFi
2010-2012 Tutor in Cell Biology at Imperial College of London (UK).
2010 PhD in Experimental and Clinical Oncology, UniFi
2006 Laurea Magistrale in Medical Biotechnologies, 110/110 cum laude at UniFi
2004 Laurea in Biotechnologies, 110/110 cum laude at UniFi
2001 Diploma at Liceo Scientifico Balducci (Firenze), 100/100
Science communication and roles of responsibility
- Supervisor for undergraduate students and MSc students responsiblefor the design and planning of the research project and the supervision of thesis writing and dissertation.
- Member of the panel of “Medical Biotechnology Master Thesis” and “Biotechnology Thesis” at University of Florence.
- Active reviewer for Cancer Research, Oncogene, Nature - Scientific Reports, Nature - Communications Biology,Trends in Molecular Medicine, Gene, Biomaterials, Cancer Letters, Carcinogenesis, Oncotarget, Hormones and Cancer, Cancer Medicine, NPJ Breast, Breast Cancer Research, BMC Cancer, BMC Biology, Frontiers in Oncology, AIMS Medical Science, Cell Stress, International Journal of Cancer, The FEBS Journal
- Reviewer for Funding Agency: Genesis Oncology Trust (New Zealand), Estonian Research Council, Breast Cancer Now (UK)
- Associate Editor and/or Editorial Board Member for the following internationally peer-reviewed journals: Nature - Scientific Reports, BMC Cancer, Hormones and Cancer, Frontiers in Oncology
Honours and awards
2017: “Guido Berlucchi Foundation Best Oral presentation Prize” awarded during the International EACR-AACR-SIC Meeting.
2017: Scientific Committee of the3rd Annual Meeting of Young SIC Investigator.
2016: “Guido Berlucchi Foundation Best Poster Prize” awarded during the Annual Meeting of the Italian Cancer Society.
2015: International Society for Cancer Metabolism (ISCaM) Young Investigator Award for the best oral communication.
2015: Chairman for the plenary section on “Targeting cancer metabolism and the altered microenvironment”. ISCaM meeting
2014: "Elena Capannini" Award for innovative anticancer therapy
2014: Chairman for the plenary section on “Cancer Microenvironment and inflammation”; SIC (Italian Association for Cancer Research) conference
2014: EACR (European Association of Cancer Research) Meeting Bursary awardee
2013: Chairman for the plenary section on “Cancer Stem Cell”; SIC conference
2013: Morandi et al. Cancer Research paper was included in the highlights 10 exciting ICR discoveries from 2012/13
2013: AACR (American Association of Cancer Research) Scholar-In-Training SIC awardee
2012: Italian Foundation for Cancer Research 3 years fellowship awardee
2012: EACR “Targeted Therapies/Signaling Pathways Symposium" proffered paper awardee
2011: Cover of Trends in Molecular Medicine issue March 2011
2019-2024: AIRC Investigator Grant (role: Principal Investigator)
2019-2021: Gender Medicine - Excellence Department grant (role: Principal Investigator)
2017-2020: AIRC-ECRF MultiUser Grant (role: Group Leader)
2017: Fondazione Umberto Veronesi postdoc fellowship
2016: Fondazione Umberto Verones postdoc fellowship
2012: AIRC/ FIRC 3-years fellowship
2019: 4th IFOM Symposium "Breaking Boundaries: Metabolism at the Cross-roads" (Milano, IT) - selected
2019: 61st Annual Meeting Italian Cancer Society "Precision Oncology: from Myth to Reality" (Napoli, IT) - selected
2019: 60th Congress of the Italian Society of Biochemistry (Lecce, IT) - invited
2018: “Signal Transduction in Cancer – ABCD Meeting” (Torino, IT) – selected, AIRC travel bursary
2018: “Pharmacological insights of altered lipid metabolism in oncological, neurological, cardiovascular, and hepatic diseases” (Padova, IT) - invited
2018:“Metabolism meets function 2018 - unraveling the role of metabolism in shaping cancer biology” (Bari, IT) - invited
2018: Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern (Bern, CH) - invited
2018: PhDay – Instituto Oncologico Veneto (Padova, IT) - invited
2018: Dipartimento di Medicina Interna, Università degli Studi di Genova - invited
2017: Breast Cancer Symposium - Cancer du Sein du Cancéropole Grand Ouest, (Nantes, FR) - invited
2017: Workshop “Targeting the metabolic deregulation of cancer: a novel pharmacological approach” (Padova, IT) - invited
2017: Cancer Metabolism symposium at the “EACR-AACR-SIC Special Conference “The Challenges of Optimising Immuno and Targeted Therapies: From Cancer Biology to the Clinic” – selected, best oral prize
2016: DENOTHE Research Center (Firenze, IT) - invited
2016: University of Sussex, Brighton (UK) - invited
2016: “REVOLUTIONARY ROAD Accelerating Conversion of Cancer Biology into Personalized Clinical Oncology” SIC Annual Conference (Verona, IT) – selected, Guido Berlucchi Award
2015: ISCaM meeting - Metabolism and Microenvironmet in Cancer Plasticity (Venezia, IT) – selected, best oral prize
2015: SIC Meeting "Signal transduction and tumor microenvironment: new opportunities for cancer therapy” (Catanzaro, IT) – invited
2012: EACR 22nd Biennial Congress (Barcelona, ES) – selected, proffered paper
Dr Morandi studies the mechanisms that govern the most common type of breast cancer, i.e. those positive for estrogen-receptor. This subset of breast cancers accounts for two in every three breast cancers and they can be treated with endocrine therapy. Despite the initial clinical benefit, patients can relapse with resistant disease. Dr Morandi is trying to identify the molecular and metabolic pathways that influence response and resistance to endocrine therapy, to identify innovative predictive markers or potential therapeutic target.
His interest in the identification of metabolic determinants of therapy resistance has been also applied to other solid cancer. The study of metabolic deregulation and reprogramming in cancer is therefore his main focus of research.